Latest news with #bioprocessing
Reuters
22-07-2025
- Business
- Reuters
Danaher lifts annual profit forecast on pharma demand, China recovery
July 22 (Reuters) - Life sciences firm Danaher (DHR.N), opens new tab raised its annual profit forecast on Tuesday, banking on steady demand for bioprocessing from its pharmaceutical clients and a recovery in China. Danaher, which provides tools and technologies that help pharmaceutical companies develop and make drugs, said demand from the industry remains strong, with robust number of clinical trials and therapies under development. CEO Rainer Blair said that patents expiring soon for several high-volume therapies is also driving demand. Danaher expects high single-digit long-term growth for its bioprocessing unit. "Monoclonal antibodies, which comprise more than 75% of our bioprocessing revenues remain the largest investment area for our customers," Blair said. Revenues in China, about 12% of total sales, remained pressured due to Chinese government policies such as volume-based procurement and reimbursement changes. But the company said its China business, barring diagnostics, is improving, as government stimulus boosts pharma and biotech industries. Danaher's current exposure to proposed tariffs stands at "a couple hundred million dollars," down from previous estimates, a company executive told analysts on a call. Still, Danaher flagged that demand from academic and government sectors remained soft due to uncertainty around research funding, while clinical diagnostics and applied markets stayed stable. Evercore analyst Vijay Kumar said Danaher has delivered a "steady print" of results, and that improving trends in China and a potential bioprocessing recovery in 2026 could boost growth. The company now forecasts annual adjusted profit per share of $7.70 to $7.80, up from its previous projection of $7.60 to $7.75. Danaher expects third-quarter revenue to rise at a low-single-digit rate from a year earlier. Second-quarter sales came in at $5.94 billion, surpassing analysts' estimates of $5.84 billion, according to data compiled by LSEG. Separately, Danaher announced that Matthew Gugino will be succeeding long-time CFO Matthew McGrew, effective February 28, 2026.
Globe and Mail
17-07-2025
- Business
- Globe and Mail
Repligen to Report Second Quarter 2025 Financial Results
WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2025 financial results on Tuesday, July 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six- month reporting periods ended June 30, 2025. The conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (800) 770-2030 for callers in the U.S., and (609) 800-9909 for international callers. Replay listeners must provide the passcode 7706699. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are 'inspiring advances in bioprocessing' for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at and follow us on LinkedIn. This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like 'believe,' 'expect,' 'may,' 'will,' 'should,' 'seek,' or 'could' and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Yahoo
05-07-2025
- Business
- Yahoo
Jim Cramer Says 'Danaher Can Make a Comeback'
Danaher Corporation (NYSE:DHR) is one of the 22 stocks Jim Cramer recently talked about. A caller inquired if Cramer thinks it is time to get back into the stock, and here's what Mad Money's host had to say in response: 'Okay, well, let me tell you, we never left it for the Charitable Trust because I have faith, ultimately, that this company will come through. Why? I've known it for 30 years. I have felt that it always does things right in the end. I am sticking by that, and I truly believe that Danaher can make a comeback. This is healthcare, a lot of IPOs are coming. They have China business. The China business isn't that bad. I am not abandoning Danaher right here.' A healthcare professional in a lab coat holding a microscope and looking at a slide under the lens. Danaher (NYSE:DHR) develops and markets products and services for medical, scientific, and industrial use. The company's technologies support bioprocessing, diagnostics, laboratory automation, genomic research, and clinical testing. While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
27-05-2025
- Business
- Globe and Mail
Scientific Industries to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
BOHEMIA, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Scientific Industries, Inc. (OTCQB: SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, announced it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025. Company Webcast The webcast presentation will take place at 12:30 p.m. ET on Thursday, May 29, 2025. The webcast can be accessed by visiting the conference home page at or directly at The webcast will also be available for replay following the event. 1x1 Meetings Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@ or register for the event at About Scientific Industries, Inc. Scientific Industries (OTCQB: SCND), is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie ® 2 Mixer and Torbal ® balances, and bioprocessing systems under the product name DOTS. Scientific Industries' products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit About Scientific Bioprocessing, Inc. Scientific Bioprocessing, Inc. (SBI) is dedicated to pioneering digitally simplified bioprocessing by providing actionable insights from lab to production floor. With a broad portfolio of state-of-the-art bioprocess sensors and actuators as well as innovative data analytics software, SBI helps scientists and engineers in bioprocessing to monitor and control critical process parameters and product quality attributes. SBI is a subsidiary of Scientific Industries Inc. (SCND-OTCQB) To learn more, visit Safe Harbor Statement Statements made in this press release that relate to future events, performance or financial results of the Company are forward-looking statements which involve uncertainties that could cause actual events, performance or results to materially differ. The Company undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statement should be read in conjunction with the additional information about risks and uncertainties set forth in the Company's Securities and Exchange Commission reports, including our annual report on Form 10-K.
Globe and Mail
22-05-2025
- Business
- Globe and Mail
Repligen Corporation to Present at William Blair Growth Conference
WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45 th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3 rd at 1:20 p.m. CT. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at and will be available for replay for a limited period of time following the event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are 'inspiring advances in bioprocessing' for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at and follow us on LinkedIn.
